Antitrust may not be drugmakers’ top policy concern
As pharmaceutical companies lobby against bipartisan efforts to curb prescription drug prices, there may be room for competition-related bills to be signed into law.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10